Camilla Jandus

University of Geneva — Switzerland

Medicine · Health Sciences

43h-index7.5kcitations202works7.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(68), Immune Cell Function and Interaction(67), Immunotherapy and Immune Responses(63), CAR-T cell therapy research(45), IL-33, ST2, and ILC Pathways(39)

Publications201 total

Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer
Nature Communications·2026Open Access
Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Cancer Immunology Research·2025
PD-1+ NK cell subsets in high grade serous ovarian cancer: an indicator of disease severity and a target for combined immune-checkpoint blockade
Journal of Experimental & Clinical Cancer Research·2025· 2 citedOpen Access
Neural anticipation of virtual infection triggers an immune response
Nature Neuroscience·2025· 15 citedOpen Access
Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer
Science Advances·2025· 3 citedOpen Access
UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity
Cell Reports Medicine·2025Open Access
Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors
Biomedicines·2025Open Access
Circulating innate lymphoid cells are dysregulated in patients with prostate cancer
Cellular & Molecular Biology Letters·2025· 4 citedOpen Access
Targeting CXCR4-expressing TAMs in muscle-invasive bladder cancer to enhance tumor control after immunotherapy
2025Open Access
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors
Preprints.org·2025· 1 citedOpen Access
STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer
Molecular and Clinical Oncology·2025· 3 citedOpen Access
Noncanonical NF-κB signaling in dendritic cells is required for ATP-driven indoleamine 2,3-dioxygenase 1 induction through P2Y11 receptor
Journal of Leukocyte Biology·2025· 2 citedOpen Access
Lymphatic-derived oxysterols promote anti-tumor immunity and response to immunotherapy in melanoma
Nature Communications·2025· 9 citedOpen Access
208P Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Immuno-Oncology Technology·2024Open Access
Robust estimation of cancer and immune cell-type proportions from bulk tumor ATAC-Seq data
eLife·2024· 2 citedOpen Access
Author response: Robust estimation of cancer and immune cell-type proportions from bulk tumor ATAC-Seq data
2024Open Access
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer
Cancer Treatment Reviews·2024· 14 citedOpen Access
Robust estimation of cancer and immune cell-type proportions from bulk tumor ATAC-Seq data
2024Open Access
Author response: Robust estimation of cancer and immune cell-type proportions from bulk tumor ATAC-Seq data
2024Open Access
page 1 of 11Next →

Frequent Co-authors

Pedro Romero(29), Daniel E. Speiser(17), Sara Trabanelli(17), Alejandra Gomez‐Cadena(8), Bérengère Salomé(8), Giuseppe Ercolano(7), Laurent Derré(7), Ping‐Chih Ho(6), Antonio Curti(6), George Coukos(5), Tania Wyss(5), David Gfeller(5), Olivier Michielin(5), Valentina Salvestrini(5), Hans‐Uwe Simon(4), Stephan von Gunten(4), Gilles Bioley(4), Jean‐Paul Rivals(4), Mara Cenerenti(4), Philippe Guillaume(4)